Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer

Cancer Biology and Therapy

Volumn 14, Issue 8, 2013, Pages 742-751

  Xie, Xiaoqi ^a   Kerrigan, John E ^a   Minko, Tamara ^b   Garbuzenko, Olga ^b   Lee, Kuo Chieh ^a   Scarborough, Alex ^a   Abali, Emine Ercikan ^a   Budak Alpdogan, Tulin ^a   Johnson Farley, Nadine ^a   Banerjee, Debabrata ^a   Scotto, Kathleen W ^a   Bertino, Joseph R ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

E2F 1; Mouse xenografts; Pegylated liposomes; Penetratin peptide; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; LIPOSOME; PENETRATIN; PENETRATIN PEPTIDE; RIBONUCLEOTIDE REDUCTASE; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BODY DISTRIBUTION; BURKITT LYMPHOMA; CANCER CELL; DNA SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; TUMOR REGRESSION;

E2F-1; MOUSE XENOGRAFTS; PEGYLATED LIPOSOMES; PENETRATIN PEPTIDE; SMALL CELL LUNG CANCER;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; CARRIER PROTEINS; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; E2F1 TRANSCRIPTION FACTOR; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; PEPTIDE FRAGMENTS; PROMOTER REGIONS, GENETIC; RANDOM ALLOCATION; RNA, MESSENGER; SMALL CELL LUNG CARCINOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881415283     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.25184     Document Type: Article

References (51)

1. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010; 120:4478-92; PMID:21099110; http://dx.doi.org/10.1172/JCI44239
2. Udayakumar T, Shareef MM, Diaz DA, Ahmed MM, Pollack A. The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy. [Review]. Semin Radiat Oncol 2010; 20:258-66; PMID:20832018; http://dx.doi.org/10.1016/j. semradonc. 2010.05.007
3. Iwamoto M, Banerjee D, Menon LG, Jurkiewicz A, Rao PH, Kemeny NE, et al. Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification. Cancer Biol Ther 2004; 3:395-9; PMID:14726656; http://dx.doi. org/10.4161/cbt.3.4.733
4. Nelson MA, Reynolds SH, Rao UN, Goulet AC, Feng Y, Beas A, et al. Increased gene copy number of the transcription factor E2F1 in malignant melanoma. Cancer Biol Ther 2006; 5:407-12; PMID:16481740; http://dx.doi.org/10. 4161/cbt.5.4.2512
5. Alonso MM, Alemany R, Fueyo J, Gomez-Manzano C. E2F1 in gliomas: a paradigm of oncogene addiction. Cancer Lett 2008; 263:157-63; PMID:18334281; http://dx.doi.org/10.1016/j.canlet.2008.02.001
6. Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K, et al. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clin Cancer Res 2007; 13:6938-46; PMID:18056168; http://dx.doi.org/10.1158/1078-0432.CCR-07- 1539
7. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435:839-43; PMID:15944709; http://dx.doi.org/10.1038/nature03677
8. Croxton R, Ma Y, Song L, Haura EB, Cress WD. Direct repression of the Mcl-1 promoter by E2F1. Oncogene 2002; 21:1359-69; PMID:11857079; http://dx.doi.org/10.1038/sj.onc.1205157
9. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem 2004; 279:40511-20; PMID:15271987; http://dx.doi.org/10.1074/jbc. M404496200
10. Engelman D, Putzer BM. The dark side of E2F-1: In transit beyond apoptosis. Cancer Res 2012; 72:2012; http://dx.doi.org/10.1158/0008-5472.CAN-11- 2575
11. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81:323-30; PMID:7736585; http://dx.doi.org/10.1016/0092-8674(95)90385-2
12. Harbour JW, Dean DC. Rb function in cellcycle regulation and apoptosis. Nat Cell Biol 2000; 2:E65-7; PMID:10783254; http://dx.doi. org/10.1038/35008695
13. Hallstrom TC, Mori S, Nevins JR. An E2F-1 gene expression program that determines the balance between proliferation and cell death. Cancer Cell 2008; 13:1311-22; http://dx.doi.org/10.1016/j. ccr.2007.11.031
14. Kong LJ, Chang JT, Bild AH, Nevins JR. Compensation and specificity of function within the E2F family. Oncogene 2007; 26:321-7; PMID:16909124; http://dx.doi.org/10.1038/sj.onc.1209817
15. Stevens C, La Thangue NB. The emerging role of E2F-1 in the DNA damage response and checkpoint control. DNA Repair (Amst) 2004; 3:1071-9; PMID:15279795; http://dx.doi.org/10.1016/j. dnarep.2004.03.034
16. Vuaroqueaux V, Urban P, Labuhn M, Delorenzi M, Wirapati P, Benz CC, et al. Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. Breast Cancer Res 2007; 9:R33; PMID:17535433; http://dx.doi.org/10.1186/bcr1681
17. Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, et al. Clinical relevance of E2F family members in ovarian cancer-an evaluation in a training set of 77 patients. Clin Cancer Res 2007; 13:144-51; PMID:17200349; http://dx.doi.org/10.1158/1078-0432.CCR-06-0780
18. De Meyer T, Bijsmans IT, Van de Vijver KK, Bekaert S, Oosting J, Van Criekinge W, et al. E2Fs mediate a fundamental cell-cycle deregulation in high-grade serous ovarian carcinomas. J Pathol 2009; 217:14-20; PMID:18991331; http://dx.doi.org/10.1002/path.2452
19. Kaelin WG Jr. E2F1 as a target: promoter-driven suicide and small molecule modulators. Cancer Biol Ther 2003; 2(Suppl 1):S48-54; PMID:14508080
20. Bertino JRD, Banerjee D. E2F-1 as an anticancer drug target. Oncology Reviews 2009; 3:207-14; http://dx.doi.org/10.1007/s12156-009-0028-1
21. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002; 297:63-4; PMID:12098689; http://dx.doi.org/10.1126/science. 1073096
22. Bertrand JR, Malvy C, Auguste T, Tóth GK, Kiss-Ivánkovits O, Illyés E, et al. Synthesis and studies on cell-penetrating peptides. Bioconjug Chem 2009; 20:1307-14; PMID:19552459; http://dx.doi. org/10.1021/bc900005j
23. Hawkins GD, Cramer CJ, Truhlar DG. Parametrized models of aqueous free energies of solvation based on pairwise descreening of solute atomic charges from a dielectric medium. J Phys Chem 1996; 100:19824-39; http://dx.doi.org/10. 1021/jp961710n
24. Eymin B, Gazzeri S, Brambilla C, Brambilla E. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene 2001; 20:1678-87; PMID:11313916; http://dx.doi.org/10.1038/ sj.onc.1204242
25. Zhang SY, Liu SC, Al-Saleem LF, Holloran D, Babb J, Guo X, et al. E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev 2000; 9:395-401; PMID:10794484
26. Alla V, Engelmann D, Niemetz A, Pahnke J, Schmidt A, Kunz M, et al. E2F1 in melanoma progression and metastasis. J Natl Cancer Inst 2010; 102:127-33; PMID:20026813; http://dx.doi.org/10.1093/jnci/djp458
27. Ma Y, Kurtyka CA, Boyapalle S, Sung SS, Lawrence H, Guida W, et al. A small-molecule E2F inhibitor blocks growth in a melanoma culture model. Cancer Res 2008; 68:6292-9; PMID:18676853; http://dx.doi. org/10.1158/0008-5472.CAN-08- 0121
28. Di Cresce C, Figueredo R, Ferguson PJ, Vincent MD, Koropatnick J. Combining small interfering RNAs targeting thymidylate synthase and thymidine kinase 1 or 2 sensitizes human tumor cells to 5-fluorodeoxyuridine and pemetrexed. J Pharmacol Exp Ther 2011; 338:952-63; PMID:21673071; http://dx.doi. org/10.1124/jpet.111.183178
29. Pakunlu RI, Wang Y, Saad M, Khandare JJ, Starovoytov V, Minko T. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release 2006; 114:153-62; PMID:16889867; http://dx.doi.org/10.1016/j.jconrel. 2006.06.010
30. Garbuzenko OB, Saad M, Betigeri S, Zhang M, Vetcher AA, Soldatenkov VA, et al. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm Res 2009; 26:382-94; PMID:18958402; http://dx.doi. org/10.1007/s11095-008-9755-4
31. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific- Discussion/human/000564/WC500025606.pdf
32. Minko T, Pakunlu RI, Wang Y, Khandare JJ, Saad M. New generation of liposomal drugs for cancer. Anticancer Agents Med Chem 2006; 6:537-52; PMID:17100558; http://dx.doi.org/10.2174/187152006778699095
33. Wang Y, Saad M, Pakunlu RI, Khandare JJ, Garbuzenko OB, Vetcher AA, et al. Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxiainducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor. Clin Cancer Res 2008; 14:3607-16; PMID:18519795; http://dx.doi. org/10.1158/1078-0432.CCR-07-2020
34. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993; 234:779-815; PMID:8254673; http://dx.doi. org/10.1006/jmbi.1993.1626
35. Martí-Renom MA, Stuart AC, Fiser A, Sánchez R, Melo F, Sali A. Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 2000; 29:291-325; PMID:10940251; http://dx.doi.org/10. 1146/annurev.biophys.29.1.291
36. Sánchez R, Sali A. Comparative protein structure modeling. Introduction and practical examples with modeller. Methods Mol Biol 2000; 143:97-129; PMID:11084904
37. Marti-Renom MA, Madhusudhan MS, Fiser A, Rost B, Sali A. Reliability of assessment of protein structure prediction methods. Structure 2002; 10:435-40; PMID:12005441; http://dx.doi.org/10.1016/S0969-2126(02)00731-1
38. Zheng N, Fraenkel E, Pabo CO, Pavletich NP. Structural basis of DNA recognition by the heterodimeric cell cycle transcription factor E2F-DP. Genes Dev 1999; 13:666-74; PMID:10090723; http://dx.doi.org/10.1101/gad.13.6.666
39. Lamazière A, Chassaing G, Trugnan G, Ayala-Sanmartin J. Tubular structures in heterogeneous membranes induced by the cell penetrating peptide penetratin. Commun Integr Biol 2009; 2:223-4; PMID:19641736; http://dx.doi.org/10.4161/cib.2.3.8073
40. Macke T, Case DA. Modeling unusual nucleic acid structures. Molecular Modeling of Nucleic Acids. N. Leontes and J. SantaLucia, Jr. Washington, DC, ACS 1998; 379-393.
41. Fraenkel E, Pabo CO. Comparison of X-ray and NMR structures for the Antennapedia homeodomain-DNA complex. Nat Struct Biol 1998; 5:692-7; PMID:9699632
42. Case DA, Cheatham TE 3rd, Darden T, Gohlke H, Luo R, Merz KM Jr., et al. The Amber biomolecular simulation programs. J Comput Chem 2005; 26:1668-88; PMID:16200636; http://dx.doi.org/10.1002/jcc.20290
43. Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ. Geometry-based flexible and symmetric protein docking. Proteins 2005; 60:224-31; PMID:15981269; http://dx.doi.org/10.1002/prot.20562
44. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 2006; 65:712-25; PMID:16981200; http://dx.doi.org/10.1002/prot.21123
45. Jorgensen W, Chandrasekhar J, Madura J, Klein M. Comparison of Simple Potential Functions for Simulating Liquid Water. J Chem Phys 1983; 79:926-35; http://dx.doi.org/10.1063/1.445869
46. Darden T, York D, Pedersen L. Particle Mesh Ewald: An N-log(N) method for Ewald sums in large systems. J Chem Phys 1993; 98:10089-92; http://dx.doi. org/10.1063/1.464397
47. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen L. A smooth particle mesh ewald potential. J Chem Phys 1995; 103:8577-92; http://dx.doi. org/10.1063/1.470117
48. Miyamoto S, Kollman P. SETTLE: An Analytical Version of the SHAKE and RATTLE Algorithms for Rigid Water Models. J Comput Chem 1992; 13:952-62; http://dx.doi.org/10.1002/jcc.540130805
49. Berendsen HJC, Postma JPM, van Gunsteren WF, DiNola A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys 1984; 81:3584-90; http://dx.doi.org/10.1063/1.448118
50. Wang J, Morin P, Wang W, Kollman PA. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. J Am Chem Soc 2001; 123:5221-30; PMID:11457384; http://dx.doi.org/10.1021/ja003834q
51. Lavery R, Moakher M, Maddocks JH, Petkeviciute D, Zakrzewska K. Conformational analysis of nucleic acids revisited: Curves+. Nucleic Acids Res 2009; 37:5917-29; PMID:19625494; http://dx.doi.org/10.1093/nar/gkp608